Cambridge Healthtech Institute’s 5th Annual

CARs, TILs, TCRs
( CAR、TIL、TCR )

Effective Strategies beyond Conventional Platforms

2020年3月10日~11日

 

The therapeutic potential of adoptive cell therapy was first acknowledged a couple of decades ago, but it was only recently that we transformed adoptive cell therapy into a viable therapeutic option for patients by the two CAR T cell therapies approved by the FDA. Although this is a very exciting time for adoptive cell therapy, there is still much to be done to reach its full potential including other novel cell therapies beyond T cells. Cambridge Healthtech Institute’s 5th Annual CARs, TILs, TCRs will gather experts in the field to address clinical progress, discuss strategies to reduce toxicity, increase efficacy, production and cost-effectiveness, along with showcasing emerging unconventional T cell and non-T cell therapies.  

Preliminary Agenda

THE PURSUIT OF TILs and TCRs

Preclinical Data and Clinical Plan for Developing Tumour-Infiltrating Lymphocytes (TILs) for Solid Tumor Indication

Robert Hawkins, MB BS, MRCP, PhD, FRCP, Cancer Research UK Professor, Medical Oncology, University of Manchester; Honorary Consultant, Medical Oncology, Christie Hospital

New Broadly Expressed Cancer Targets from Successful TIL Therapy

Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine

TCR-Engineered T Cells Combined with T Cell Co-Stimulation to Treat Solid Tumors

Reno Debets, PhD, Associate Professor, Laboratory of Tumor Immunology, PI, Medical Oncology, Erasmus MC-Cancer Institute

NOVEL ENGINEERING APPROACHES FOR NEXT-GENERATION T CELL THERAPY

Immunotherapy in Ovarian Cancer: Are We There Yet?

George Coukos, Full Professor and Director, Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL); Director, Lausanne Branch, Ludwig Institute of Cancer Research; Chief, Service of Immuno-oncology, CHUV

Cars, Trucks, and Beyond: The Next Generation of Adoptive T Cell Therapy

Hinrich Abken, PhD, Professor, Chair Gene-Immunotherapy, Regensburg Center for Interventional Immunology, University of Regensburg

New Horizons for Adoptive T Cell Therapy

Phil Darcy, PhD, Professor, NHMRC Principal Research Fellow, Laboratory Head Cancer Immunotherapy, Peter MacCallum Cancer Centre

Exploiting the NKG2D Receptor for Autologous and Allogeneic CAR T Cell Therapy of Cancer

David E. Gilham, PhD, Vice President, R&D, Celyad

CARs and Armored CARs

Renier Brentjens, MD, PhD, Director, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center; Professor, Pharmacology, Weill Cornell Graduate School of Medical Sciences

PANEL DISCUSSION

Promising Approaches for Solid Tumours – Where We Are and Where We Are Going

Moderator: John Maher, FRCPath, PhD, Consultant & Senior Lecturer, Immunology, Cancer Studies, King’s College London

 

* 活动内容有可能不事先告知作更动及调整。